NASDAQ · NRCTechnologyR&D — Physical & Biological Sciences

NRC Health financials

$21.05+4.94%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$137.4M$143.1M$148.6M$151.6M$148.0M$133.8M$128.0M$119.7M
Gross profit$85.0M$86.1M$92.6M$151.6M$148.0M$133.8M$128.0M$119.7M
Gross margin61.9%60.2%62.3%100.0%100.0%100.0%100.0%100.0%
Operating income$22.6M$35.2M$40.0M$46.5M$50.3M$42.7M$43.0M$35.3M
Net income$11.3M$24.8M$31.0M$31.8M$37.5M$37.3M$32.4M$25.4M
Net margin8.2%17.3%20.8%21.0%25.3%27.8%25.3%21.2%
Diluted EPS$0.50$1.04$1.25$1.27$1.46$1.45$1.26$1.04
EBITDA$30.2M$41.2M$45.9M$51.8M$56.6M$50.2M$48.6M$40.7M
Operating cash flow$26.4M$34.6M$38.1M$36.3M$46.3M$40.6M$40.9M$39.8M
Free cash flow$15.7M$19.2M$22.3M$26.4M$40.8M$36.7M$36.3M$33.9M
Diluted shares22.4M23.7M24.7M25.1M25.6M25.7M25.7M24.4M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$4.1M$4.2M$6.7M$25.0M$54.4M$34.7M
Short-term investments$0.00$0.00$0.00$0.00——
Total debt$79.0M$62.7M$36.7M$22.2M$26.5M$30.6M
Total assets$134.9M$132.5M$122.4M$130.5M$157.5M$133.4M
Total liabilities$120.9M$101.3M$73.5M$58.4M$72.2M$69.1M
Shareholders' equity$14.0M$31.3M$49.0M$72.0M$85.3M$64.3M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology